CAPTRUST Financial Advisors
CEROW

CAPTRUST Financial Advisors’s CERo Therapeutics Warrants CEROW Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,432
Closed -$1.61K – 2815
2023
Q3 		$1.61K Sell
22,432
-7,648
-25% -$547 ﹤0.01% 2566
2023
Q2 		$1.83K Hold
30,080
– – ﹤0.01% 2507
2023
Q1 		$905 Buy
+30,080
New +$1.36K ﹤0.01% 2303
2022
Q4 		– Sell
-27,699
Closed -$2K – 2202
2022
Q3 		$2K Buy
+27,699
New +$2.33K ﹤0.01% 2053

Other funds holding CEROW

SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return

CAPTRUST Financial Advisors's CEROW Position: Q4 2023 in Review

CAPTRUST Financial Advisors sold out of CERo Therapeutics Warrants (CEROW) in Q4 2023, closing a stake of 22,432 shares — an estimated $1.61K sold.

CAPTRUST Financial Advisors first reported a position in CEROW in Q3 2022 and held it in 4 quarters. The position peaked at $2K in Q3 2022. 40 funds tracked by Wall St. Rank hold CEROW as of Q4 2023.

  • CAPTRUST Financial Advisors reported no remaining CERo Therapeutics Warrants position as of Q4 2023 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 22,432 CERo Therapeutics Warrants shares in Q4 2023, an estimated $1.61K.
  • CAPTRUST Financial Advisors first reported a position in CERo Therapeutics Warrants in Q3 2022 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's CERo Therapeutics Warrants position peaked at $2K in Q3 2022.
  • 40 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.